Vax-CAR-NK / Vaxcell-Bio Therap, Y-Biologics - LARVOL DELTA

VaxCell-Bio partners with ProBio to accelerate CAR-related therapies development (Korea Biomedical Review) - "VaxCell-Bio...said it signed a memorandum of understanding (MOU) with ProBio, a global contract development and manufacturing organization (CDMO), to accelerate the development of its chimeric antigen receptor (CAR)-related therapies...Under this agreement, the two companies will collaborate on the development, manufacturing, and clinical processes of CAR therapies in compliance with good manufacturing practices (GMP), with a focus on antibody drug development, gene and cell therapy-based drug discovery, and the creation of advanced pharmaceutical manufacturing processes....VaxCell-Bio is optimistic that its partnership with ProBio, a company with extensive experience in cell therapy development and commercialization, will provide a solid foundation for its ongoing projects, including dual-target CAR-T, CAR-MILs, and CAR-NK platform therapies."

Licensing / partnership • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Hepatocellular Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Vaxcell Bio forms a scientific advisory group and launches an integrated R&D center [Google translation] (HIT News) - "Vaxcell Bio...launched a new scientific advisory group and integrated and expanded its research and development (R&D) organization...Vaxcell Bio signed a one-year advisory contract with new scientific advisory committee members, including Dr. Byeong-wook Ryu, who has led the research and development of CAR-T treatments in the United States, and Professor Seung-hwan Lee, a professor at the University of Ottawa in Canada, who is considered an authority on immune cell therapy research and development. It was announced on the 14th that it was done....'With the joining of the two scientists, the research and development of CAR-T, CAR-NK, and CAR-MILs, the Vax-CAR platform built by Vaxcell Bio, will accelerate and will have the effect of being recognized externally.'"

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor

Y-Biologics transfers antibody sequence tech to VaxCell Bio (Korea Biomedical Review) - "Y-Biologics said Wednesday that it has signed a licensing-out deal with VaxCell Bio, a company specializing in anticancer immune cell therapies, for its anti-PD-L1 antibody 'YBL-007' sequence. Under the agreement, VaxCell Bio has the exclusive right to use the YBL-007 sequence in the research, development, and commercialization of CAR-T (chimeric antigen receptor T-cell) or CAR-NK (chimeric antigen receptor natural killer cell) therapeutics. YBL-007 is an antibody that targets the immune checkpoint protein PD-L1. The antibody binds to PD-L1 on the surface of cancer cells."

Licensing / partnership • Oncology